1. Introduction {#sec1}
===============

Women using hormonal contraception (HC) exhibit smaller free cortisol responses than naturally cycling (NC) women to psychosocial stressors, physical stressors, and even athletic competitions ([@bib12]; [@bib42]; [@bib57], [@bib58]), despite HC and NC women showing similar diurnal cortisol rhythms ([@bib83]). Methodologically, however, although menstrual cycle phase is controlled and reported for NC women, studies examining differences between HC and NC women rarely report or control for position in the HC cycle. Lack of reporting or controlling whether HC women are in the active, hormone-containing phase, or inactive, no-hormone phase, of the HC cycle makes it difficult to interpret how HC is leading to reported differences. For instance, various forms of HC have been shown to increase corticosteroid binding globulin ([@bib86]), which could explain the reduced salivary cortisol response to stress observed with HC but would likely only be seen during the active HC phase. Yet, this is only one possibility. The synthetic estradiol, ethinyl estradiol, and synthetic progestins contained in HC affect a multitude of systems beyond the reproductive system. Further complicating matters are findings showing that the different progestins can affect these systems differently, which makes understanding the mechanisms at play substantially more difficult. One way to begin uncovering which mechanism(s) contribute to the effect of HC on the stress response is to investigate patterns across the active and inactive HC phases.

A less intensively studied portion of the hypothalamo-pituitary-adrenal (HPA) axis is the adrenal progesterone response to stress. The adrenal release of progesterone in response to stress is well documented in animal models and men ([@bib6]; [@bib7]; [@bib11]; [@bib14]; [@bib16]; [@bib19]; [@bib22]; [@bib62], [@bib63]), with more limited work investigating the response in women ([@bib10]; [@bib23]; [@bib34]; [@bib67]; [@bib88]). Even more limited is work examining this portion of the HPA response in women using HC ([@bib87]), which also did not report HC cycle phase.

In this preliminary report on the effects of HC phase on free cortisol and progesterone response to stress, women were exposed to cold pressor stress during either the active or inactive HC phase. We hypothesized that both cortisol and progesterone responses would differ between the active and inactive HC phases, such that responses would be larger during the inactive phase when synthetic hormones are no longer available to impact systems which might limit adrenal steroid response to stress. In a post-hoc analysis we also tested whether the class of progestins in the HC formulations was related to the magnitude of the free cortisol and progesterone responses to stress. The classes of progestins contained in HC are referred to as generations and are typically characterized by what the progestin was derived from ([@bib13]): first-generation progestins are created from estranes derived from testosterone or from pregnanes derived from 17-OH progesterone, second-generation progestins are created from gonanes derived from testosterone, third-generation progestins are created from second-generation gonane derivatives, and fourth-generation progestins are created from non-ethylated estranes or from pregnanes.

2. Materials and methods {#sec2}
========================

Eighty-five participants were recruited from the University of Southern California psychology subject pool and provided written informed consent approved by the University of Southern California Institutional Review Board. Eligibility criteria included using monophasic oral HC containing 4--7 inactive days, or vaginal rings, for a minimum of 2 months. Additional eligibility criteria included being a non-smoker, having no chronic illness contraindicated for exposure to the cold pressor task, no pregnancy or nursing within the last 12 months, and no use of medications that might affect the stress response (e.g., corticosteroids, beta-blockers, and anxiolytics). See [Table 1](#tbl1){ref-type="table"} for demographic information.Table 1Demographic and mood information for all participants.Table 1Age (years) Mean19.8 Range18--23Education (years) Mean13.9 Range12--16Ethnicity (n) Non-Hispanic61 Hispanic7 Decline to State2Race (n) American Indian/Alaska Native0 Asian14 Pacific Islander/Native Hawaiian0 Black or African American0 White37 More than one race14 Unknown or not reported5Trait Anxiety Active41.8 Inactive39Depression Active16.8 Inactive15.3Time of year tested (n) September11 October15 November21 December4 January3 February12 March7 April12[^1]

Women were tested once during either the active or inactive phase of their HC regimen. During the sessions, women provided 3 saliva samples and completed the cold pressor test ([@bib52]). The cold pressor test (CPT) involved holding their dominant hand in ice-cold water (0--3 °C) for up to 3 min and has been shown to effectively increase salivary cortisol levels over the tested time course in our ([@bib34], [@bib35]; [@bib47], [@bib48], [@bib49]) and other ([@bib8]; [@bib9]; [@bib57], [@bib58]; [@bib68]) labs. Prior to beginning the CPT, participants were instructed to keep their hand immersed up to the wrist for as long as possible up to 3 min, at which time the researcher would terminate the task. Throughout the duration of hand immersion, a researcher watched the participant while holding a stopwatch the participant was unable to see.

Salivary samples are a reliable source for determining biologically available, unbound, levels of hormones ([@bib18]; [@bib29]; [@bib79]; [@bib84]). Participants passively drooled ∼1 mL of saliva into a collection tube for each sample. To ensure stable baseline hormone levels, sessions were conducted in the afternoons between 1200 h and 1800h, and participants were asked to refrain from food/drink within 1 h, sleep within 3 h, and caffeine, alcohol, and exercise within 24 h of their session start time. Women arrived for sessions an average of 23 min prior to CPT exposure, during which time they drank 8oz of water to clean the mouth for saliva samples (completed at least 10 min before the first saliva sample was collected) and completed questionnaires (i.e., demographics and mood measures). Saliva samples were collected prior to CPT (baseline), immediately after the hand was removed from the water (0 m post offset), and 15 min after the hand was placed in the water (15 m post onset). The 15 m-post-onset time point was selected for consistency with our previous work ([@bib34], [@bib35]), which aimed to have cognitive tasks performed during the peak times for salivary cortisol reactivity, between 21 and 40 min after stressor onset ([@bib15]). All samples were processed for cortisol and progesterone using Salimetrics, LLC (State College, PA) ELISA kits and measured optically using Molecular Devices, LLC SpectraMax M3 Multi-mode Microplate Reader (Sunnyvale, CA). The inter- and intra-assay variations for cortisol (6.5%; 11.6%) and progesterone (10.4%; 16.5%) were within the expected ranges from our lab.

Fifteen women were excluded; four for using multiphasic HC, two for unknown HC day, one for not yet taking the first pill of her current pack, seven for not completing the stress task, and one for insufficient sleep the night prior (\<2 h). Two baseline cortisol outliers, both in the active phase, were excluded from the cortisol analyses, and three progesterone baseline outliers, one in the inactive phase and two in the active phase, were excluded from the progesterone analyses. Due to their low enrollment (n = 4 per HC phase), women using fourth-generation formulations were also excluded from analyses. With these exclusions, cortisol analyses included 32 active HC phase women and 28 inactive HC phase women, while progesterone analyses included 30 active HC phase women and 27 inactive HC phase women (see [Table 2](#tbl2){ref-type="table"} for HC information).Table 2Breakdown of the different hormonal contraceptive formulations used by all participants.Table 2ProgestinActive NInactive NProgestin GenerationEthinyl Estradiol Dose (mg)Progestin Dose (mg)Number of Inactive PillsHC Formulation3832**Ethynodiol Diacetate10    ** Zovia1010.0351.007**Norethindrone Acetate46    ** Gildess0210.0201.007 Menastrin0110.0201.004 Minastrin1010.0201.004 Gildess Fe 1/201110.0201.007 Junel Fe0210.0201.007 Junel Fe 1/201010.0201.007 Microgestin Fe1010.0201.007**Norethindrone43    ** GeneressFe1010.0250.804 Microgestin1110.0301.507 Nortrel0110.0350.507 Microgestin Fe0110.0301.507 Ortho Novum1010.0351.007 Wymzya Fe1010.0350.404**Levonorgestrel1410    ** Aubra1320.0200.107 Aviane1020.0200.107 Chateal1120.0300.157 Levora2120.0300.157 Lutera7420.0200.107 Portia1020.0300.157 Sronyx0120.0200.107 Amethia Lo1020.0200.107**Norgestrel11    ** Elinest0120.0300.307 Lo\'Ovral1020.0300.307**Etonorgestrel53    ** NuvaRing5330.0150.127**Norgestimate55    ** Estarylla0130.0350.257 Mononessa1130.0350.257 Previfem1130.0350.227 Sprintec2130.0350.257 Ortho Cyclen1130.0350.257**Drospirenone44    ** Gianvi0140.0203.004 Loryna1040.0203.007 Ocella1040.0303.007 Safyral0140.0303.007 Vestura1040.0203.004 Yaz1040.0203.004 Zarah0140.0303.007 Generic Drospirenone0140.0303.007[^2]

Statistical analyses were conducted using SPSS. The baseline cortisol and progesterone outliers were identified as values more extreme than 1.5x the interquartile range using boxplots. 3 (progestin generation) x 2 (HC phase) x 3 (time) mixed-model ANOVAs were conducted to test changes in cortisol and progesterone responses between women seen during the active and inactive HC phases using different generation progestins. Bonferroni Corrected pairwise comparisons for time and progestin generation were modeled into the ANOVAs. Follow-up analyses were conducted where appropriate.

3. Results {#sec3}
==========

3.1. Influence of progestin generation on cortisol response to CPT between the HC phases {#sec3.1}
----------------------------------------------------------------------------------------

Over half the women held their hand in the ice water for the full 3 min, with only eight women removing their hand before completing 1 min. There was no relationship between immersion time and salivary cortisol reactivity 15 m post onset (*r* = −0.086, *p* = .480, n = 70).

CPT increased free cortisol levels over time across generations and HC phase, *F*~(2,108)~ = 20.929, *p* \< .001, η~p~^2^ = 0.279. There was a significant generation × time interaction, *F*~(4,108)~ = 3.836, *p* = .006, η~p~^2^ = 0.124, suggesting that cortisol response to CPT differed between generations 1, 2, and 3 (see [Fig. 1](#fig1){ref-type="fig"}). Follow-up analyses revealed that women using generation 1 progestins experienced significant increases in free cortisol over time, *F*~(2,34)~ = 4.722, *p* = .016, η~p~^2^ = 0.217, although pairwise comparisons revealed this was only driven by marginally higher free cortisol levels 15 m post onset compared with 0 m post offset, *p* = .072, 95% CI = −0.003, 0.088. Women using generation 2 progestins also showed significant increases in free cortisol over time, *F*~(2,46)~ = 17.255, *p* \<. 001, η~p~^2^ = 0.429, driven by significantly higher free cortisol levels at 15 m post onset than at baseline, *p* = .001, 95% CI = 0.053, 0.210, or at 0 m post offset, *p* = .001, 95% CI = 0.042, 0.187. Women using generation 3 progestins only exhibited marginally significant changes across time, *F*~(2,34)~ = 2.735, *p* = .079, η~p~^2^ = 0.139, with no differences in pairwise comparisons between baseline, 0 m post offset, and 15 m post onset (see [Fig. 1](#fig1){ref-type="fig"}).Fig. 1**Salivary cortisol response to cold pressor stress within different progestin generations.** The two-way time × generation interaction was significant. Women using formulations containing first-generation progestins showed a main effect of time, but pairwise comparisons revealed no differences between specific timepoints for the first-generation progestins. Women using formulations containing second-generation progestins showed significant increases in free cortisol levels at the 15 m-post-onset time point compared to the baseline and 0 m-post-offset time points. Women using formulations containing third-generation progestins showed no change in cortisol. \**p* \< .05, \*\**p* ≤ .01, \*\*\**p* ≤ .001.Fig. 1

Pairwise comparisons indicate the larger free cortisol response in women using second-generation progestins was driven by the free cortisol response during the inactive HC phase. Women using second-generation progestins and seen during the inactive phase showed a significant increase in free cortisol levels 15 m post onset compared with baseline, *p* = .003, 95% CI = 0.056, 0.286, while women seen during the active phase did not, *p* = .079, 95% CI = −0.009, 0.203 (see [Fig. 2](#fig2){ref-type="fig"}). The three-way generation x HC phase × time interaction was not significant, *F*~(4,108)~ = 1.223, *p* = .305, η~p~^2^ = 0.043.Fig. 2**Salivary cortisol response to cold pressor stress during the active and inactive hormonal contraceptive phases within different progestin generations.** Pairwise comparisons indicate women using second-generation progestins showed a significant increase in free cortisol levels at the 15 m-post-onset time point compared with baseline during the inactive phase, while women seen during the active phase did not. The three-way phase x time × generation interaction was not significant. \*\**p* ≤ .01.Fig. 2

3.2. Influence of progestin generation on progesterone response to CPT between the HC phases {#sec3.2}
--------------------------------------------------------------------------------------------

CPT increased free progesterone levels over time across generations and HC phase, *F*~(2,102)~ = 3.847, *p* = .025, η~p~^2^ = 0.070. There was a significant HC phase × generation interaction, *F*~(2,51)~ = 3.706, *p* = .031, η~p~^2^ = 0.127, driven by higher progesterone levels during the active phase in women using generation 1 progestins, *p* = .047, 95% CI = 0.779, 123.728 (see [Fig. 3](#fig3){ref-type="fig"}). The three-way generation x phase × time interaction was not quite significant, *F*~(4,102)~ = 2.102, *p* = .086, η~p~^2^ = 0.076. Follow-up analyses of the active group revealed no effect of time, generation, or interactions with progesterone response. In contrast, in the inactive phase group there was a significant time × generation interaction, *F*~(4,48)~ = 3.300, *p* = .018, η~p~^2^ = 0.216, suggesting that progestin generation differentially affected progesterone responses to CPT during the inactive phase only. Additional follow-up analyses of the inactive HC phase group revealed that women using either generation 1 progestins, *F*~(2,14)~ = 0.902, *p* = .428, η~p~^2^ = 0.114, or generation 3 progestins, *F*~(2,14)~ = 2.997, *p* = .083, η~p~^2^ = 0.300, did not experience significant increases in progesterone over time, whereas women using generation 2 progestins did show significant increases in progesterone, *F*~(2,20)~ = 5.435, *p* = .013, η~p~^2^ = 0.352, driven by significantly higher progesterone levels 15 m post onset compared with baseline, *p* = .036, 95% CI = 2.614, 78.908 (see [Fig. 3](#fig3){ref-type="fig"}).Fig. 3**Salivary progesterone response to cold pressor stress during the active and inactive hormonal contraceptive phases within different progestin generations.** The three-way phase x time × generation interaction was not significant. However, there was a two-way phase × generation interaction. Women using formulations containing first-generation progestins showed significantly lower overall progesterone levels during the inactive phase. There also was significant time × generation interaction when looking only at the inactive phase where only women using formulations containing second-generation progestins showed a significant progesterone response to stress. This was not observed in women using formulations containing first- or third-generation progestins. \**p* \< .05.Fig. 3

4. Discussion {#sec4}
=============

We examined whether free cortisol and free progesterone responses to cold pressor stress differed in women during the active and inactive HC phases. We found that although free cortisol response to stress did not systematically differ between phases, there was an effect of progestin generation. Women whose HC formulation contained second-generation progestins showed more robust free cortisol responses 15 m post-stress onset than women using formulations containing first- or third-generation progestins. Pairwise comparisons suggest the larger free cortisol response in women using second-generation progestins are driven by larger responses during the inactive HC phase than the active HC phase. Unlike the free cortisol response, we did find a significant effect of HC phase on CPT-induced progesterone response, with women experiencing a progesterone response during the inactive HC phase only. Interestingly, this effect was also limited to women using HC formulations containing second-generation progestins.

These progesterone response findings extend previous work suggesting that progesterone is released from the adrenal gland in addition to the ovaries in women ([@bib87]) and findings that CPT increases progesterone in naturally cycling women ([@bib34]). Although progesterone is a known portion of the HPA axis response ([@bib11]; [@bib19]; [@bib23]; [@bib62]; [@bib88]), it is more difficult to ascertain whether stress-induced progesterone increases are of an adrenal or ovarian source in naturally cycling women ([@bib87]). Finding a progesterone response during the active HC phase would be a clear indicator of adrenal progesterone release since HC inhibits ovarian production of progesterone by preventing ovulation ([@bib51]). However, our current results indicate that the progesterone response is observed during the inactive HC phase only, and only within users of second-generation progestins. The overall pattern suggests that the same or similar mechanisms of HC use which limit the free cortisol response to stress also limit stress-induced progesterone release.

Why free cortisol and progesterone responses differ as a function of progestin generation is difficult to elucidate as the synthetic hormones contained in HC affect so many systems, further complicated by progestins within a generation often times exerting different effects across systems (for reviews see, [@bib2]; [@bib72], [@bib73], [@bib74]). Since the effects of progestin generation on cortisol and progesterone response appear limited to women using second-generation progestins, it is likely that the mechanisms driving the effects are similar. These effects include, but are not limited to, the upregulation of the corticosteroid binding globulin ([@bib86]), sex hormone binding globulin ([@bib24]; [@bib59]; [@bib80]), and altering both high-density and low-density lipoprotein cholesterol levels ([@bib3]; [@bib25]; [@bib26]; [@bib44]; [@bib82]; [@bib89]).

4.1. Corticosteroid binding globulin levels {#sec4.1}
-------------------------------------------

A likely candidate mechanism for the smaller stress-induced free cortisol responses observed in prior research when comparing HC women to NC women ([@bib12]; [@bib42]; [@bib57], [@bib58]) is the upregulating effect of the estradiol component of HC on corticosteroid binding globulin levels ([@bib86]). Although to different degrees, the progestins are anti-estrogenic (for review see, [@bib70]), leading to the possibility that second-generation progestins exert a greater anti-estrogenic effect on corticosteroid binding globulin upregulation and blunt this effect relative to first- and third-generation progestins. Lesser upregulation of corticosteroid binding globulin relative to the other progestin generations would result in a greater level of free, unbound, cortisol. However, levonorgestrel, the most used second-generation progestin in our sample, does not appear to block or lessen the estrogen-induced increase in corticosteroid binding globulin, with some even reporting greater corticosteroid binding globulin upregulation in formulations using levonorgestrel ([@bib1]; [@bib20]; [@bib32]; [@bib43]; [@bib65]; [@bib76]). As such this does not appear to be a differentiating mechanism between progestin generations.

4.2. Competitive binding to corticosteroid binding globulin {#sec4.2}
-----------------------------------------------------------

Progesterone binds to corticosteroid binding globulin with some affinity ([@bib17]). Coupled with evidence that progestins contained in HC promiscuously bind to other receptor complexes, such as glucocorticoid receptors (for reviews see, [@bib66]; [@bib70], [@bib71]; [@bib72], [@bib73], [@bib74]), perhaps progestins contained in HC also have some binding affinity to corticosteroid binding globulin. This could account for the observed pattern of results without affecting the estrogen-related upregulation of corticosteroid binding globulin. This would require that second-generation progestins display a relatively greater affinity for corticosteroid binding globulin than first- and third-generation progestins, comparatively displacing the amount of cortisol able to bind to the plasma protein, leading to higher levels of free cortisol. However, studies have shown that despite the varying affinity to other receptor complexes such as androgen, glucocorticoid, and mineralocorticoid receptors, synthetic progestins preferentially bind to sex hormone binding globulin and do not bind to corticosteroid binding globulin is any significant manner ([@bib20]; [@bib32]; [@bib45]; [@bib66]).

4.3. Androgens and androgenicity {#sec4.3}
--------------------------------

Androgen levels are negatively correlated with glucocorticoid responses to stress. In rodent models, orchiectomy, or removal of the testes, is associated with larger corticosterone responses to multiple stressors, an effect often reversed with androgen replacement (for reviews see, [@bib27]; [@bib33]). Yet, despite HC-induced decreases in free androgen levels ([@bib83]), studies consistently find that HC users show smaller free cortisol responses than non-users ([@bib12]; [@bib42]; [@bib57], [@bib58]), suggesting the reductions in androgen levels are not a primary contributor to the HC-related effect on cortisol response.

Although HC inhibits the endogenous production and release of androgens, the synthetic progestins contained in HC differentially bind to and activate androgen receptors (for reviews see, [@bib66]; [@bib70], [@bib71]; [@bib72], [@bib73], [@bib74]). The varying androgenicity of the progestins may contribute to the differences in free cortisol response to stressors across progestin generation, with more androgenic progestins leading to blunted cortisol responses to stress. However, levonorgestrel, the most prevalently used second-generation progestin in this study, is highly androgenic ([@bib39]; [@bib46]; [@bib55]; [@bib66]; [@bib70]; [@bib73]; [@bib80]). Thus, despite the negative relationship between androgens and the steroid response to stress, the androgenicity of progestins does not appear to impart a similar effect on the stress steroid response.

4.4. Androgen metabolites {#sec4.4}
-------------------------

The presumed mechanism of action for androgen-related blunting of the steroid response to stress (for reviews see, [@bib27]; [@bib33]), would be direct action of androgens on androgen receptor complexes. Thus, it would follow that progestins that bind to and activate the androgen receptor would also be associated with relatively smaller cortisol responses. However, research suggests it is not activation of the androgen receptor complex that directly inhibits the stress response. For instance, flutamide, a classic androgen receptor antagonist ([@bib56]), failed to fully block the dihydrotestosterone (DHT)-related dampening of HPA axis reactivity ([@bib53], [@bib54]). DHT is a potent androgen that is converted from testosterone by the 5-alpha reductase enzyme. Thus, finding that an androgen receptor antagonist does not block the ability of DHT to dampen the HPA response suggests that classic androgen receptor is not involved in quieting the stress response. Rather, evidence suggests the primary mechanism for androgen-related quiescence of the HPA response is through androgen metabolites, particularly the DHT metabolite 5α-androstan-3β,17β-diol (3β-diol), via action on the estrogen receptor β ([@bib54]).

Reports that androgen metabolites and/or androgen action via estrogen receptor β suggests that the androgenicity of a progestin would not contribute to the relative magnitude of the stress steroid response. Importantly, if the mechanism of action for androgen-related quiescence of HPA reactivity is related to androgen metabolites, then the affinity of the progestin for the androgen receptor is irrelevant as these synthetic hormones will not be converted to androgen metabolites.

4.5. 17β-estradiol and estrogenicity {#sec4.5}
------------------------------------

HC use results in very low estradiol levels (for review see, [@bib61]). Based on work showing post-menopausal women randomly assigned to 17β-estradiol showed blunted cortisol responses to CPT stress compared with women receiving placebo ([@bib35]), HC-related blunting of estradiol levels should be associated with greater free cortisol response to stressors. Yet, that is not the case ([@bib12]; [@bib42]; [@bib57], [@bib58]).

According to the above-reviewed work suggesting that the androgen-related blunting of the HPA axis is a function of androgen metabolite activation of the estrogen receptor β ([@bib54]), it may be that the relative estrogenicity of HC is affecting the stress steroid response. If some progestins exert their anti-estrogenic effects (for review see, [@bib70]) by having antagonistic effects on the estrogen receptor β, this may contribute to the larger relative free cortisol responses to stress in second-generation progestins such as levonorgestrel, which some have reported to be highly anti-estrogenic ([@bib24]; [@bib66]). However, this theoretical assertion can only address the interaction between time and generation on free cortisol response, not the findings from follow-up analyses showing the cortisol response was larger during the inactive phase only.

4.6. Cholesterol levels {#sec4.6}
-----------------------

Cholesterol is the precursor to sex and stress steroids. Levels of high-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol are reportedly affected by HC, although the pattern of effects are mixed ([@bib3]; [@bib5]; [@bib25]; [@bib26]; [@bib40]; [@bib44]; [@bib78]; [@bib82]; [@bib85]; [@bib90]; [@bib89]). Importantly, LDL and HDL cholesterol can lead to increased cortisol levels in a dose-dependent manner *in vitro* and *in vivo* ([@bib31]; [@bib50]; [@bib77]; [@bib91]). Additionally, smaller cortisol responses are reportedly related to human patient populations with fewer LDL receptors ([@bib37], [@bib38]).

This may be one potential mechanism for greater cortisol response in users of second-generation progestins, although results are mixed. Some reports indicate that levonorgestrel increases LDL levels ([@bib41]; [@bib44]; [@bib73], [@bib74]) and decreases HDL ([@bib3]; [@bib25]; [@bib26]; [@bib40]; [@bib41]; [@bib55]; [@bib65]; [@bib74]; [@bib78]; [@bib89]), while other reports indicate deceases in LDL ([@bib25]; [@bib69]), or no effect on HDL, LDL, or both ([@bib26]; [@bib40]; [@bib44]; [@bib69]; [@bib82]; [@bib89]). These mixed effects appear to be, in part, a result of progestin dosage, whether administered alone or in combination with ethinyl estradiol, or duration of use. Further complicating this matter are additional mixed results regarding whether LDL or HDL cholesterol levels and/or receptors are the primary contributor to corticosteroidogenesis ([@bib4]; for review see, [@bib30]; [@bib31]; [@bib37]; [@bib38]; [@bib50]).

4.7. Conclusions {#sec4.7}
----------------

Discussed herein are six possible mechanisms for our observed pattern, none of which offers a straightforward account for why second-generation containing HC formulations are associated with a relatively larger free cortisol response to cold pressor stress. Other possible mechanisms may also drive this effect including, but not limited to, the imbalance between endogenous hormone production and levels and receptor activation; progestins exerting differential effects higher up in the HPA axis, such as the hypothalamus (i.e., corticotropin releasing factor) or the pituitary (i.e., adrenocorticotropin); differential effects on the endocannabinoid system, which is also involved in suppressing corticotropin releasing hormone neurons and terminating the HPA response ([@bib21]; for review see, [@bib36]) and interacts with sex steroids and the hypothalamo-pituitary-gonadal axis (for review see, [@bib28]); and differential binding to mineralocorticoid receptors, which exhibit a high affinity for glucocorticoids and are theorized to regulate both the basal and stress-induced levels of glucocorticoids ([@bib64]; [@bib81]).

Our study was a preliminary investigation into how the adrenal response to stressors varies across the hormonal contraceptive cycle. Although our hypotheses did not require inclusion of these factors, the study would have been strengthened by including a naturally cycling group and a no-stress condition, as well as including additional extended time points for salivary cortisol testing. An important next step is to replicate the observed progestin generation pattern while potentially also including for comparison a naturally cycling group and/or a no-stress control condition. Inclusion of additional time points for salivary cortisol analysis would also be useful to see if the time course of cortisol reactivity differs across the HC phase. For instance, women might return to baseline levels faster during one phase over the other, or have different delays in reaching peak cortisol levels. Though the 15 m-post-onset time point is commonly used in studies assessing reactivity to CPT ([@bib8]; [@bib34], [@bib35]; [@bib57], [@bib58]), and cortisol does not increase significantly from 15 to 30 min ([@bib8]) nor from 15 to 42 min post onset ([@bib34]), finding differences with additional later time points is plausible given work showing not only a delay between plasma and salivary cortisol levels but also peak levels occurring approximately 40 min after stress exposure ([@bib18]; [@bib29]). We also did not record what time of day participants typically took their oral contraception. Given that different progestins are metabolized at different rates and can reach peak serum levels at different times (for review see, [@bib2]), this information would have been useful in further investigating these generational effects. Another aim for future research on this topic will be *a priori* inclusion of progestin generation, which will help address issues related to power that the post-hoc nature of our analyses cannot address. Despite these limitations, this preliminary work highlights the need to better understand how hormonal contraception is affecting women beyond the reproductive, cardiovascular, and lipid outcomes typically measured. Furthermore, as evident in our discussion of possible mechanisms, this approach will need to be multifaceted and translational, with the use of animal models to help determine the physiological and behavioral phenotypes observed in women.
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[^1]: Women did not differ on scores of depression (CES-D; [@bib60]) or trait anxiety (STAI-Y2; [@bib75]) between the HC phases. Women were tested during the fall and spring academic semesters.

[^2]: N is reported for each progestin and corresponding HC formulations for the active and inactive groups. Ethinyl estradiol and progestin dosages and number of inactive pills or days are also reported.
